The Abu Dhabi Health Services Company (SEHA), a subsidiary of PureHealth – the largest healthcare platform in the Middle East, has announced that Tawam Hospital has successfully treated a three-year-old boy from Gaza who was suffering from a retinoblastoma tumour.
SEHA shared that the young boy underwent a special assessment plan with targeted interventions following medical examinations and advanced diagnostic procedures. This included an eye examination under anaesthesia using a brain and orbit MRI.
The paediatric oncology and ophthalmology teams at Tawam Hospital closely collaborated to treat the boy with systemic chemotherapy while awaiting definitive ocular treatments.
As part of a comprehensive follow-up plan, the boy will require regular eye check-ups under general anaesthesia to assess his retina.
The follow-up sessions will serve to monitor his progress and assess the need for potential intraocular and systemic chemotherapy treatments.
Speaking about the treatment, Saeed Jaber Al Kuwaiti, Group Chief Executive Officer of SEHA, said: “The success of the complex retinoblastoma tumour management at Tawam Hospital is a testimony of PureHealth’s and SEHA’s commitment to providing world-class, patient-centered care at its facilities. The condition required urgent attention, more so given the age of the child and the risks of metastases.”
Al Kuwaiti added: “The success of the therapeutic approach reinforces the diagnostic and surgical excellence across the SEHA’s network and the dedication of our paediatric oncology and ophthalmology teams. Under the leadership of PureHealth, we are committed to deliver the highest standards of healthcare as part of our mission to ensure people’s health and longevity.”